Artiva Biotherapeutics (ARTV) closed at $3.96 on November 16, 2026, down 1.2% from the previous close, on volume of 1,239,791 shares (30-day average 1,030,747).
Data as of November 16, 2026.
16-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
ACCESS Newswire (Fri, 13-Nov 10:30 AM ET)
PRNewswire (Thu, 12-Nov 10:15 AM ET)
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK
Globe Newswire (Tue, 27-Oct 7:30 AM ET)
Globe Newswire (Fri, 2-Oct 9:05 AM ET)
Globe Newswire (Thu, 1-Oct 7:30 AM ET)
Globe Newswire (Wed, 23-Sep 7:30 AM ET)
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Globe Newswire (Thu, 17-Sep 8:00 AM ET)
Globe Newswire (Tue, 8-Sep 7:30 AM ET)
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
Globe Newswire (Wed, 2-Sep 8:30 AM ET)
Market Chameleon (Mon, 8-Jun 5:25 AM ET)
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Artiva Biotherapeutics trades on the NASDAQ stock market under the symbol ARTV.
As of November 16, 2026, ARTV stock price declined to $3.96 with 1,239,791 million shares trading.
ARTV has a beta of 3.96, meaning it tends to be more sensitive to market movements. ARTV has a correlation of 0.18 to the broad based SPY ETF.
ARTV has a market cap of $193.60 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that ARTV belongs to (by Net Assets): VTI, IWM, VXF, VTWO, VFMO.
ARTV has outperformed the market in the last year with a return of +21.8%, while the SPY ETF gained +11.3%. However, in the most recent history, ARTV shares have underperformed the stock market with its stock returning -65.4% in the last 3 month period and -5.5% for the last 2 week period, while SPY has returned -4.4% and -1.6%, respectively.
ARTV support price is $3.83 and resistance is $4.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARTV shares will trade within this expected range on the day.